The European Medicines Agency has accepted the Marketing Authorization Application for Teva and Medincell’s olanzapine long-acting injectable, TEV-'749, moving the treatment one step closer to potential approval in Europe. The filing acceptance is a regulatory milestone, but it does not yet imply approval or commercial launch. The news is positive for both companies, though the immediate market impact is likely limited.
The European Medicines Agency has accepted the Marketing Authorization Application for Teva and Medincell’s olanzapine long-acting injectable, TEV-'749, moving the treatment one step closer to potential approval in Europe. The filing acceptance is a regulatory milestone, but it does not yet imply approval or commercial launch. The news is positive for both companies, though the immediate market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
